Key result
Endothelial dysfunction bridges MINOCA and INOCA, underscoring the need for mechanism-targeted diagnostic and therapeutic care.
Why the study?
MINOCA and INOCA are increasingly recognised syndromes where endothelial dysfunction links vascular biology to clinical ischaemia, but their mechanisms and clinical approaches require clarification.
Endothelial dysfunction serves as the mechanistic bridge in MINOCA and INOCA, highlighting the importance of a mechanism-based diagnostic pathway and tailored medical therapy.
Answers are grounded in this paper and cite their sources.
Encourages mechanism-based phenotyping in MINOCA/INOCA; extends mechanistic framework but leaves therapeutic benefit open to prospective validation.
Myocardial infarction with non-obstructive coronary arteries (MINOCA) and ischaemia with non-obstructive coronary artery disease (INOCA) are increasingly recognised syndromes in which endothelial dysfunction forms the mechanistic bridge between vascular biology and clinical ischaemia. In health, the endothelium preserves vascular homeostasis by regulating tone, platelet activity, and inflammation; when this regulation fails, vessels assume a pro-constrictive, pro-thrombotic, and pro-inflammatory state capable of causing epicardial vasospasm, microvascular dysfunction, or plaque erosion—provoking genuine infarction and arrhythmias despite unobstructed arteries. This paper follows the continuum from these mechanisms to their clinical expression. It traces the evolution from early angiographic observations to contemporary imaging such as CMR, IVUS, and OCT, and outlines a chronological diagnostic pathway from the emergency department to the catheterisation laboratory. Subtle but actionable clues are highlighted across the clinical history, ECG, echocardiography, and angiography, demonstrating that a positive, mechanism-based diagnosis of endothelial dysfunction is feasible even when invasive testing is unavailable. Management is directed by the dominant mechanism calcium-channel blockers and nitrates for vasospastic angina; β-blockers or metabolic agents for microvascular angina supported by endothelial stabilisers, cardiac rehabilitation, and psychosocial care. Persistent endothelial dysfunction is associated with later heart-failure development, particularly HFpEF, emphasising the need for early recognition and tailored therapy. The chapter concludes with real-world challenges and emerging perspectives, including standardised testing, AI-assisted imaging, and precision therapeutics. Ultimately, understanding endothelial dysfunction links mechanisms to clinical practice, reframing MINOCA and INOCA as diagnosable and treatable syndromes that demand mechanism-based, preventive care.
No takes yet. Share an insight, caveat, or question.
Rakesh Sharma (2026) conducted a review in Myocardial infarction with non-obstructive coronary arteries (MINOCA) and ischaemia with non-obstructive coronary artery disease (INOCA). Endothelial dysfunction serves as the mechanistic bridge in MINOCA and INOCA, demanding a mechanism-based approach for diagnosis and targeted preventative care.
Synapse has enriched 10 related papers. Consider them for comparative context: